When is off-label drug use in the patient's best interest?
Philip J
PJ
Rosenfeld
Kenneth W
KW
Goodman
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004992:Ethics, Medical; D006801:Humans; D000069285:Infliximab; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D010817:Physician-Patient Relations; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab